EMA, the European Commission (EC) and the Heads of Medicines Agencies (HMA) are phasing out the extraordinary regulatory flexibilities for medicines put in place during the COVID-19 pandemic to help address regulatory and supply challenges arising from the pandemic.
This follows the end of the COVID-19 public health emergency declared by WHO in May 2023.
Post
Nessun commento:
Posta un commento